UK Economy at Risk as Ambassador Warns of Crippling Energy Costs and Pharma Threat
Table of Contents
The United Kingdom’s standing as a leading global economy is increasingly vulnerable due to persistently high energy prices and escalating disputes over pharmaceutical pricing, according to warnings issued by the US ambassador to the UK, Warren Stephens. Speaking at an event held at the Savoy Hotel on Wednesday, November 5, 2025, Stephens underscored the urgent need for comprehensive reforms to avert significant economic damage.
Energy Costs: A “Chief Obstacle” to Growth
Stephens characterized the UK’s energy costs – consistently among the highest globally – as the “chief obstacle” to sustained economic growth. “Energy costs in the United Kingdom are too high on which to run an industrialized economy,” he stated. The ambassador emphasized the widespread concern among businesses across all sectors, noting that energy expenses consistently make the UK a less attractive and more challenging location for operations. “Every business I meet, in every sector, complains to me that energy costs make the UK an expensive, and difficult, place to do business. It does not take an economic savant to know that is not a good combination.”
He further stressed that a fundamental shift in UK energy policy is paramount to securing the nation’s economic future. “Improving the economy all starts and ends with energy. If there are not major reforms to UK energy policy, then the UK’s position as a premier global economy is vulnerable.”
Trump’s Previous Criticism of UK Energy Policy
These concerns echo previous statements made by US President Donald Trump, who has previously criticized the UK’s approach to green energy. In a speech delivered at the United Nations, Trump warned that “The North Sea is so highly taxed that no developer, no oil company can go there.” This highlights a broader tension between the two nations regarding energy policy and investment incentives.
Pharmaceutical Industry Faces Potential Exodus
Beyond energy, Stephens also raised serious concerns about the future of the UK’s pharmaceutical industry. He warned that US-based pharmaceutical companies may be forced to close their UK facilities if the National Health Service (NHS) does not increase its payments for drugs. “If there are not changes made and fast, pharma businesses will not only cancel future investments, they will shut down their facilities in the UK,” Stephens cautioned. “This would be a major blow to a country that prides itself, rightly so, on its life sciences sector.”
The potential for closures comes as the UK government considers raising the amount the NHS pays pharmaceutical firms by up to 25 percent. This move is intended to preempt potential tariffs threatened by President Trump, who is seeking greater alignment on global drug prices.
US Pressure on Drug Pricing and Investment Pauses
The dispute over drug pricing has already begun to impact investment decisions. Recent reports indicate that US companies Merck and AstraZeneca have paused or scrapped planned investments in the UK, directly linked to the ongoing disagreement. According to sources, officials have proposed raising the NHS’s pricing threshold by a quarter to the Trump administration. The US President is reportedly seeking to address the significant price disparity between the American pharmaceutical market and those in other countries, threatening tariffs of up to 100 percent on pharmaceutical imports if a resolution is not reached.
The situation presents a complex challenge for the UK, balancing the need to maintain affordable healthcare with the imperative to attract and retain vital foreign investment in a crucial sector of the economy. The coming months will be critical in determining whether the UK can navigate these pressures and safeguard its economic standing.
